



Published in final edited form as:

*Cell Stem Cell*. 2018 February 01; 22(2): 206–220.e4. doi:10.1016/j.stem.2017.12.017.

## Phospholipid remodeling and cholesterol availability regulate intestinal stemness and tumorigenesis

Bo Wang<sup>1,2</sup>, Xin Rong<sup>1,2</sup>, Elisa N.D. Palladino<sup>5</sup>, Jiafang Wang<sup>3</sup>, Alan M. Fogelman<sup>4</sup>, Martín G. Martín<sup>3</sup>, Waddah A. Alrefai<sup>6</sup>, David A. Ford<sup>5</sup>, and Peter Tontonoz<sup>1,2,7,\*</sup>

<sup>1</sup>Department of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90272 USA

<sup>2</sup>Molecular Biology Institute, David Geffen School of Medicine, University of California, Los Angeles, CA, 90272 USA

<sup>3</sup>Department of Pediatrics, Division of Gastroenterology and Nutrition, Mattel Children's Hospital, David Geffen School of Medicine, University of California, Los Angeles, CA, 90272 USA

<sup>4</sup>Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, 90272 USA

<sup>5</sup>Department of Biochemistry and Molecular Biology, and Center for Cardiovascular Research, Saint Louis University, St. Louis, MO 63104 USA

<sup>6</sup>Research and Development, Jesse Brown VA Medical Center, Chicago, Illinois, United States of America, Division of Gastroenterology and Hepatology, Department of Medicine, University of Illinois at Chicago, Chicago, IL USA

### Summary

Adequate availability of cellular building blocks, including lipids, is a prerequisite for cellular proliferation, but excess dietary lipids are linked to increased cancer risk. Despite these connections, specific regulatory relationships between membrane composition, intestinal stem cell (ISC) proliferation and tumorigenesis are unclear. We reveal an unexpected link between membrane phospholipid remodeling and cholesterol biosynthesis and demonstrate that cholesterol itself acts as a mitogen for ISCs. Inhibition of the phospholipid-remodeling enzyme *Lpcat3* increases membrane saturation and stimulates cholesterol biosynthesis, thereby driving ISC proliferation. Pharmacologic inhibition of cholesterol synthesis normalizes crypt hyperproliferation in *Lpcat3*-deficient organoids and mice. Conversely, increasing cellular

\*Correspondence: ptontonoz@mednet.ucla.edu.

<sup>7</sup>Lead Contact

#### Author Contributions

B.W., X.R., E.N.D.P. performed experiments. B.W., X.R., D.A.F., A.M.F. and P.T. designed experiments and interpreted data. J.W., M.G.M., A.M.F., W.A.A. provided essential reagents and interpreted data. B.W., D.A.F. and P.T. wrote the paper.

#### Declaration of Interests


A.M.F. is a principal and an officer in Bruin Pharma.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

cholesterol content stimulates crypt organoid growth, and providing excess dietary cholesterol or driving endogenous cholesterol synthesis through SREBP-2 expression promotes ISC proliferation *in vivo*. Finally, disruption of Lpcat3-dependent phospholipid and cholesterol homeostasis dramatically enhances tumor formation in *Apc<sup>min</sup>* mice. These findings identify a critical dietary-responsive phospholipid-cholesterol axis regulating ISC proliferation and tumorigenesis.

## In brief

Tontonoz and colleagues show that the phospholipid remodeling enzyme Lpcat3 regulates intestinal stem cell and progenitor cells by stimulating cholesterol biosynthesis. Furthermore, enhancing cholesterol availability, either by providing it in the diet or through genetic manipulation, promotes tumorigenesis in *Apc<sup>min/+</sup>* mice.



## Introduction

Mammalian cell proliferation requires adequate supply of energy and cellular building blocks, including phospholipids and cholesterol—two major components of cellular membranes (Boroughs and DeBerardinis, 2015; Ito and Suda, 2014). In addition to their roles as biomass components, phospholipids and cholesterol play regulatory roles as signaling molecules that engage specific receptors and transcription factors (Repa and Mangelsdorf, 2000; Simons and Toomre, 2000; Spector and Yorek, 1985). It has also become clear that dynamic changes in phospholipid and cholesterol metabolism can impact membrane composition and alter membrane biophysical properties, thereby influencing a variety of cell processes (Holzer et al., 2011; Spector and Yorek, 1985). In normal tissues, tissue-restricted adult stem cells undergo rapid self-renewal and differentiation to maintain tissue homeostasis. Whether changes in phospholipid or cholesterol metabolism or membrane composition may affect stem cell function is not well understood.

The small intestine is an excellent model system to study adult stem cell biology. Vigorous self-renewal of the intestinal epithelium is essential for optimal gut function. A small number of intestinal stem cells (ISCs) in the crypts continuously divide to produce daughter stem cells and highly proliferative progenitor cells called transit-amplifying (TA) cells (Barker, 2014). The latter migrate from the crypt and differentiate into all of the cell types in the intestinal villi, including absorptive enterocytes, secretory goblet cells, enteroendocrine cells and Paneth cells. Proper balance between ISC self-renewal and differentiation is crucial to preserve the integrity of the intestinal epithelium and maintain its homeostasis (Simons and Clevers, 2011). Dysregulation of intestinal homeostasis is known to cause severe intestinal pathologies, including cancer. ISCs have been shown to be the cells of origin for the intestinal tumors that develop in mice carrying mutations in tumor suppressor gene adenomatous polyposis coli (*Apc*) (Barker et al., 2009; Schwitalla et al., 2013).

Prior studies have suggested links between phospholipid metabolism and intestinal tumorigenesis, although the underlying mechanisms remain to be fully elucidated. Polymorphisms in the secretory phospholipase A2 (*Pla2g2a*) gene, which encodes an enzyme catalyzing the deacylation of *sn*-2 fatty acids during phospholipid remodeling, influences the incidence of intestinal tumors in *Apc* multiple intestinal neoplasia (Min) mice (Dietrich et al., 1993; MacPhee et al., 1995). Loss of *Pla2g2a* function increases *Apc*<sup>min</sup>-induced tumor number (Kennedy et al., 1995), whereas overexpression of *Pla2g2a* reduces tumor multiplicity and size (Cormier et al., 1997). In contrast, deletion of another phospholipase A2 member, cytosolic phospholipase A2 (*Pla2g4*) has been reported to suppress *Apc*<sup>min</sup>-induced tumorigenesis (Hong et al., 2001). Although it is still unknown how these phospholipases affect tumor initiation and growth, such studies suggest that phospholipid remodeling may be involved in intestinal tumorigenesis. Similarly, cholesterol consumption has long been associated with increased gastrointestinal cancer risk in epidemiological studies (Jarvinen et al., 2001); however, the causal mechanisms have been largely unexplored. Given that ISCs are the cells of origin of intestinal tumors, it is reasonable to speculate that phospholipid remodeling and cholesterol availability may contribute to tumorigenesis by modulating ISC function.

In this study, we investigated whether and how phospholipid and cholesterol metabolism regulate the proliferation of ISC and progenitor cells. We recently identified the phospholipid-remodeling enzyme, lysophosphatidylcholine acyltransferase 3 (Lpcat3), as a critical determinant of membrane phospholipid composition (Rong et al., 2013). Lpcat3 catalyzes the incorporation of polyunsaturated fatty acids at the *sn*-2 site of lysophospholipids, giving rise to polyunsaturated phospholipids. Loss of Lpcat3 selectively reduces polyunsaturated phosphatidylcholine (PC) in membranes, resulting in decreased membrane fluidity (Rong et al., 2015; Wang et al., 2016). Here we show that Lpcat3 deficiency in intestine enhances ISC proliferation through induction of cholesterol biosynthesis. We demonstrate that cholesterol acts as a mitogen for ISCs and that increasing cellular cholesterol content is sufficient to drive stem cell proliferation both *in vivo* and *ex vivo*. Finally, we show that loss of Lpcat3 or activation of SREBP-2 in *Apc*<sup>min</sup> mice markedly promote intestinal tumor formation. These findings reveal a previously unrecognized link between phospholipid remodeling and cholesterol metabolism that modulates intestinal stem cell homeostasis and tumorigenesis.

## Results

### Loss of *Lpcat3* in intestine induces crypt hyperproliferation

In the course of characterizing intestine-specific *Lpcat3*-deficient mice (*Lpcat3*<sup>F/F</sup>, *Cre*<sup>Vil</sup>) (Wang et al., 2016), we noted mucosal hypertrophy in the duodenum and jejunum with profound lengthening of villi and longer small intestines. Since hypertrophy of villi is often observed as a compensatory enlargement of the absorptive surface in response to malabsorption, we conducted further studies to investigate whether this phenotype was a direct or indirect consequence of *Lpcat3* deletion in intestinal epithelium. To circumvent the problem of developmental compensation, we crossed *Lpcat3*-floxed mice with inducible villin-*Cre* mice (el Marjou et al., 2004) to generate tamoxifen-inducible intestine-specific knockout mice (*Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup>). At 8 weeks of age, we treated *Lpcat3*<sup>F/F</sup> and *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup> mice with tamoxifen to activate *Cre* recombinase activity. Realtime PCR confirmed >90% reduction in *Lpcat3* mRNA in knockout intestines 3 weeks after tamoxifen injection (Figure S1A). *Lpcat3* expression remained very low in *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup> mice, even 14 weeks post injection (Figure S1G), indicating that *Cre* recombinase was also activated in the ISC population (considering the rapid turnover of intestinal epithelium).

Acute *Lpcat3* inactivation induced a rapid loss of body weight (up to 10%), but the mice regained body weight after 2~3 weeks (Figure S1B). Similar to constitutive *Lpcat3*<sup>F/F1</sup>, *Cre*<sup>Vil</sup> mice, the length and diameter of *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup> intestines were longer and wider than those of control intestines (Figures S1C and S1D). Although histological analysis did not show multiple branched villi, acute loss of *Lpcat3* induced expanded crypt height, indicating hyperproliferation of crypts (Figure 1A). Quantification revealed an approximate 2-fold increase in crypt height and a slight increase in villus length in *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup> mice compared to floxed littermate controls (Figure 1B). There was no change in crypt density (Figure S1E). Similar phenotypes were observed in female mice and male mice even 14 weeks post tamoxifen injection (Figures S1F and S1G-S1I). The fact that these changes appeared after tamoxifen treatment in adult *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup> mice fed a low-fat chow diet suggested that they were unlikely to be secondary to altered lipid absorption.

To further investigate potential intrinsic effects of *Lpcat3* activity on crypt proliferation and epithelial turnover, we examined the incorporation and migration of ethynyl-2'-deoxyuridine (EdU)-labelled cells at 2 h, 24 h and 48 h post EdU pulse labelling (Figure 1C). As shown in Figure 1C, there was ~ 3-fold increase in EdU-positive proliferating cells in crypts of *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup> mice and these proliferative cells migrated much higher along the villus than they did in their control counterparts. Specifically, at 24 h EdU-labeled cells migrated to the tip of villi in *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup> intestines, while they reached only 1/3 of the villus height in control intestines.

To assess the impact of *Lpcat3* deficiency on ISC frequency and differentiation, we performed immunostaining for several cell markers in tamoxifen-treated control and *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup> mice. Immunohistochemistry analysis for Olfactomedin 4 (Olfm4), a marker of Lgr5+ ISCs (van der Flier et al., 2009), showed a ~53% increase in Olfm4+ cells in *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup> jejunum compared to those in *Lpcat3*<sup>F/F</sup> controls (Figures 1D). Similarly, immunostaining for Id1, a marker of both stem cells and progenitor cells (Zhang

et al., 2014), revealed a ~2-fold increase in Id1+ cells in Lpcat3-deficient intestines compared to controls (Fig. 1E), suggesting that both ISCs and progenitor cells were hyperproliferative. Increased numbers of Id1+ cells were also observed in *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* colon (Figure S1J). By contrast, loss of Lpcat3 reduced the frequency of Lysozyme + Paneth cells and PAS+ goblet cells by 52% and 35%, respectively (Figures S2A and S2B), whereas the frequency of chromogranin A1 (ChgA)+ enteroendocrine cells were not affected (Figure S2C). We did not observe a change in inflammatory cytokine expression in enterocytes of Lpcat3-deficient mice (Figure S2D)

### Phospholipid remodeling regulates crypt organoid growth *ex vivo*

To further investigate the effect of Lpcat3 deficiency on the proliferation of ISCs, we employed an *ex vivo* culture system to assess the ability of isolated intestinal crypts to form organoids in 3-D culture as described previously (Sato et al., 2009). Consistent with crypt hyperproliferation *in vivo*, loss of Lpcat3 led to an increase in size, number and complexity (higher number of buds) of organoids (Figures 2A–2D). Thus, loss of Lpcat3 enhanced ISC proliferation both *in vivo* and *ex vivo*, demonstrating that the effects were intrinsic to the ISCs.

To gain insight into how the enzymatic activity of Lpcat3 was linked to ISC proliferation, we performed lipidomic analyses on isolated crypts. Consistent with our previous observations in enterocytes, Lpcat3 deficiency in crypts selectively decreased polyunsaturated (18:2- and 20:4-containing) PC, concomitant with an increase in saturated and monosaturated PC (Figure S3A). Total PC content was not altered by Lpcat3 deficiency (Figure S3B). Arachidonic acid is a substrate for prostaglandin E2 (PGE2) biosynthesis catalyzed by cyclooxygenases (Cox-1 and Cox-2). Prior studies have demonstrated that PGE2 augments ISC function to facilitate regeneration after injury (Cohn et al., 1997; Houchen et al., 2000; Miyoshi et al., 2017). Given that loss of Lpcat3 might lead to an accumulation of AA, we considered the possibility that increased PGE2 production could be involved in Lpcat3 deficiency-induced ISC proliferation. However, the expression of the PGE2 biosynthetic enzymes *Cox-1* and *Cox-2* was not altered by Lpcat3 deficiency (Figure S3C), and PGE2 levels were decreased rather than increased in Lpcat3-deficient intestines (Figure S3D). Thus, Lpcat3-dependent ISC hyperproliferation was unlikely to be mediated by PGE2.

The above findings suggested that the change in ISC proliferation in *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* mice was caused by the change in membrane phospholipid composition *per se*. We therefore assessed the effects of different PC species on crypt organoid growth. We treated crypt cultures with liposomes containing saturated (16:0/18:0) or polyunsaturated (16:0/20:4) PC. Treatment with liposomes containing 16:0/20:4 PC significantly reduced the size, complexity, and colony formation efficiency in organoids derived from Lpcat3-deficient crypts (Figures 2E–2H). Interestingly, compared to treatment with PBS control, saturated 16:0/18:0 PC treatment increased organoid size, without affecting their structure or number.

We next assessed the effect of different PC species on the self-renewal capacity of ISCs by passaging the primary organoids in the presence of PC treatment. As shown in Figure 2I, Lpcat3-deficient primary organoids generated more secondary organoids than WT primary organoids. Moreover, exposure of the cells to 16:0/20:4 PC liposomes reduced secondary

organoid formation in *Lpcat3*-deficient organoids. By contrast, neither saturated nor polyunsaturated PC affected the growth or self-renewal of organoids from WT crypts (Figures 2E–2I). These findings are consistent with the expectation that active *Lpcat3* in WT cells continuously remodels phospholipids to maintain their composition. Together, these data directly implicate membrane phospholipid composition as a determinant of ISC proliferation and self-renewal.

### **Lpcat3 deficiency induces cholesterol biosynthesis**

To begin to explore mechanisms underlying crypt hyperproliferation in the absence of *Lpcat3*, we analyzed the expression of genes involved in several signaling pathways known to promote ISC proliferation, including Wnt, Notch and Yap pathways (Fevr et al., 2007; Gregorieff et al., 2015; VanDussen et al., 2012). Expression of mRNAs encoding mediators in these pathways was not altered in *Lpcat3*-deficient crypts compared to controls (Figures S4A and S4B). The PPAR $\delta$  pathway has recently been implicated in regulating ISC proliferation during high-fat diet feeding (Beyaz et al., 2016). We found no change in the expression of PPAR $\delta$  target genes between *Lpcat3*-deficient and control crypts (Figure S4C). These data collectively suggested that alternative mechanisms were likely to be driving proliferation in the absence of *Lpcat3*.

To uncover such mechanisms and to determine the consequence of loss of *Lpcat3* activity for intestinal cell gene expression, we profiled gene expression in crypts isolated from WT and *Lpcat3*-deficient mice. Strikingly, Gene Ontology (GO) analysis revealed strong enrichment for genes involved in sterol biosynthetic processes in the absence of *Lpcat3* (Figure 3A). Expression of the majority of the genes in the cholesterol biosynthetic pathway was increased by ~1.5 to ~2.6 fold (Figure 3B). These changes were validated by realtime PCR (Figure 3C). Similarly, expression of several cholesterol biosynthetic genes was also upregulated in *Lpcat3* deficient colons (Figure S4D). Western blot analysis revealed a marked increase in nuclear SREBP-2 in *Lpcat3*-deficient crypts (Figure 3D), suggesting that post-transcriptional activation of SREBP-2 likely drive the enhanced expression of cholesterol biosynthesis. Interestingly, the effect of *Lpcat3* deficiency was selective for SREBP-2 compared to SREBP-1 target genes. There was only a slight increase in *Srebf1c* and *Fasn* expression, while the expression of other SREBP-1 target genes was not altered (Figure S4E). In agreement with the augmented cholesterol biosynthetic gene expression, cellular free cholesterol content was increased by ~25% in *Lpcat3*-deficient crypts compared to controls (Figure 3E). To exclude the possibility that augmented cholesterol biosynthesis was secondary to chronic metabolic changes as a result of higher proliferation, we tested the consequences of acute suppression of *Lpcat3* expression *ex vivo*. We isolated crypts from *Lpcat3<sup>F/F</sup>* and *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* mice and induced Cre recombinase activity in the presence of 4-hydroxytamoxifen (4-OHT). 4-OHT treatment in organoids from *Lpcat3<sup>F/F</sup>*, *Cre<sup>ERT2</sup>* crypts increased expression of a battery of cholesterol biosynthetic genes compared to those treated with DMSO control (Figure 3F). As expected, 4-OHT treatment had no effect in organoids from *Lpcat3<sup>F/F</sup>* crypts. Consistent with our observations *in vivo*, *Srebf1* target genes were negligibly affected by acute loss of *Lpcat3* *ex vivo* (Figure S4F). These data suggest that cholesterol biosynthesis is directly coupled with phospholipid remodeling in the intestine.

## Inhibition of cholesterol biosynthesis rescues hyperproliferation

To determine whether there might be a functional relationship between cholesterol biosynthesis and crypt hyperproliferation, we first tested if blocking cholesterol biosynthesis could rescue the phenotype. Indeed, suppression of cholesterol biosynthesis by low dose simvastatin (an Hmgcr inhibitor; 1  $\mu$ M) or Ro 48-8071 (an Lss inhibitor, 1  $\mu$ M) treatment inhibited the growth of *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* crypts (Figure 4A). Supplementation of the cultures with mevalonate at levels sufficient to permit protein prenylation but not sterol synthesis (Rowell et al., 1997), did not rescue the inhibition by either Simvastatin or Ro 48-8071. By contrast, administration of cholesterol, but not epicholesterol, fully rescued organoid growth (Figure 4A and S5A), confirming that sterol synthesis is required for crypt proliferation *ex vivo*.

Next we examined if inhibition of cholesterol biosynthesis could normalize crypt hyperproliferation *in vivo*. We gavaged tamoxifen-injected *Lpcat3<sup>F/F</sup>* and *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* mice with Ro 48-8071, which has previously been shown to suppress cholesterol biosynthesis in intestine (Chuang et al., 2014). Histological analysis revealed an appreciable decrease in crypt height in *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* mice treated with Ro 48-8071 compared to those treated with vehicle control (Fig. 4B). Quantification showed a ~15% decrease in crypt height, while villus length was not affected by Ro 48-8071 treatment (Figures 4B and S5B). In contrast to *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* mice, no overt histological differences were observed in *Lpcat3<sup>F/F</sup>* control mice treated with Ro 48-8071 and vehicle. EdU-labeling analysis demonstrated an even more pronounced effect of Ro 48-8071 on ISC and progenitor cell proliferation. There was a ~45% decrease in EdU-positive proliferating cells in *Lpcat3*-deficient mice treated with Ro 48-8071 compared to those treated with vehicle (Figure 4C). Again, no difference was observed in *Lpcat3<sup>F/F</sup>* control mice between Ro 48-8071 and vehicle treatment. More importantly, Ro 48-8071 treatment reduced the number of Olfm4+ and Id1+ ISCs and progenitor cells in *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* intestines, but had no effect in *Lpcat3<sup>F/F</sup>* control intestines (Figures 4D, S5C and S5G). The frequency of Paneth cells and goblet cells was not affected by Ro 48-8071 treatment (Figures S5D and S5E). Furthermore, the inhibition of crypt proliferation by Ro 48-8071 was not secondary to increased cell apoptosis, because there was no difference in cleaved caspase-3 immunostaining between groups (Figure S5F). Thus, inhibition of endogenous cholesterol synthesis partially rescued the hyperproliferation observed in the setting of *Lpcat3* deficiency, consistent with the hypothesis that excess cholesterol synthesis was driving proliferation in this context. Importantly, however, inhibition of cholesterol synthesis did not impair normal crypt proliferation in control mice, likely due to the availability of sufficient exogenous cholesterol to support the normal rate of proliferation.

## Excess cholesterol drives ISC proliferation

We next tested if increasing cellular cholesterol content *per se* was sufficient to promote crypt proliferation. We cultured crypts isolated from C57BL/6 mice in the presence of cyclodextrin-cholesterol complexes to forcibly load the cells with excess cholesterol (Christian et al., 1997; Klein et al., 1995). Remarkably, cholesterol administration increased the size of organoids without affecting colony formation efficiency (Figure 5A), suggesting that cholesterol acts as a mitogen for ISCs. To test this notion *in vivo*, we fed C57BL/6 mice

with a 1.25% cholesterol diet for 2 weeks, and analyzed ISC and progenitor cell proliferation by EdU labeling (Figure 5B). We found a ~20% increase in EdU-positive proliferating cells in mice fed cholesterol diet compared to those fed chow diet (Figure 5B). Immunostaining showed a corresponding increase in Olfm4+ ISCs (Figure 5C). Furthermore, cholesterol diet feeding resulted in a ~15% increase in free cholesterol content in purified crypts (Figure S6A). Thus, excess exogenous (dietary) cholesterol is a stimulus for ISC proliferation in WT mice.

To address whether increased endogenous cholesterol synthesis was a stimulus for ISC proliferation we analyzed intestinal-specific *Srebf2* transgenic mice (Ma et al., 2014). These mice have enhanced cholesterol biosynthesis and increased cellular cholesterol levels specifically in enterocytes. Interestingly, similar to *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* mice, *Villin-Srebf2* transgenic mice also have longer intestines, consistent with the hypothesis that augmented cholesterol biosynthesis may promote intestinal crypt growth. In further support of this idea, EdU labeling revealed a ~60% increase in EdU-positive cells in *Villin-Srebf2* transgenic mice compared to littermate control mice (Figure 5D). Moreover, immunostaining showed ~50% more Olfm4+ and Id1+ ISCs and progenitor cells in *Villin-Srebf2* transgenic mice compared to controls (Figure 5E and S6B). Passaging of primary organoids demonstrated a ~40% and 2-fold increase in secondary organoid formation in MβCD-cholesterol treated and *Srebf2* Tg organoids, respectively (Figure 5F). Thus, increased endogenous cholesterol biosynthesis and cholesterol content is sufficient to drive ISC and progenitor cell proliferation and ISC self-renewal.

### Loss of *Lpcat3* dramatically enhances tumor formation

Given that ISCs have been demonstrated to be cells of origin for intestinal tumors, we hypothesized that *Lpcat3* might impact intestinal tumorigenesis. To test this idea, we crossed *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* mice with *Apc<sup>min</sup>* mice to generate *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>, Apc<sup>min</sup>* and *Lpcat3<sup>F/F</sup>, Apc<sup>min</sup>* control mice. At 6 weeks of age, we i.p. injected *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>, Apc<sup>min</sup>* and *Lpcat3<sup>F/F</sup>, Apc<sup>min</sup>* mice with tamoxifen to activate *Cre* recombinase activity. Similar to *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>* mice, *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>, Apc<sup>min</sup>* mice exhibited a slight loss of body weight within the first 2 weeks and regained body weight at 3 weeks post tamoxifen injection (Figure 6A). Surprisingly, however, their body weight dropped precipitously thereafter, and ~80% of *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>, Apc<sup>min</sup>* mice died 4–5 weeks after *Lpcat3* inactivation (Figures 6A and 6B). In contrast, most of the *Lpcat3<sup>F/F</sup>, Apc<sup>min</sup>* mice survived until 12 weeks post tamoxifen injection. Hematocrit analysis revealed a marked reduction in red blood cell mass in *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>, Apc<sup>min</sup>* mice (Figures 6C and 6D), which likely contributed to their moribundity. Since intestinal tumors cause bleeding and anemia in *Apc<sup>min</sup>* mice, this finding suggested a worsening of the intestinal pathology in the absence of *Lpcat3*. Indeed, gross examination and histological analysis showed that *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>, Apc<sup>min</sup>* intestines were overwhelmed with tumors, whereas *Lpcat3<sup>F/F</sup>, Apc<sup>min</sup>* control intestines developed only sporadic tumors at this age (Figures 6F and 6G). Quantification of tumor numbers showed a >10-fold increase in Duodenum and Jejunum, and ~3-fold increase in Ileum and colon of *Lpcat3<sup>F/F</sup>, Cre<sup>ERT2</sup>, Apc<sup>min</sup>* compared to *Lpcat3<sup>F/F</sup>, Apc<sup>min</sup>* mice (Figure 6E).



Loss of Lpcat3 on an *Apc*<sup>+/+</sup> background did not cause a change in inflammatory cytokine expression (Figure S2D) or marked infiltration of F4/80+ or Ly6G+ inflammatory cells (Figure S7A, B), suggesting that inflammation was unlikely to be the driver of tumor formation in the absence of Lpcat3. Although the expression of several cytokines was increased in *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup>, *Apc*<sup>min/+</sup> mice compared to *Apc*<sup>min/+</sup> mice (Figure S7C), we speculate that this may be secondary to the massive tumor burden in *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup>, *Apc*<sup>min/+</sup> mice. We did not observe obvious infiltration of inflammatory cells by Ly6G and F4/80 staining (Figure S7A, B). Similar to *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup> mice on the *Apc*<sup>+/+</sup> background, the expression of cholesterol biosynthetic genes was increased in small intestine in *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup>, *Apc*<sup>min/+</sup> mice compared to *Lpcat3*<sup>F/F</sup>, *Apc*<sup>min/+</sup> mice (Figure 6H). Interestingly, some of these genes were also upregulated in *Apc*<sup>min/+</sup> mice compared to WT mice (Figure S7D). These data suggested that Lpcat3 deficiency might enhance tumor growth by inducing cholesterol biosynthesis.

To directly test if increased cholesterol biosynthesis promotes intestinal tumorigenesis, we crossed *Srebf2* Tg mice with *Apc*<sup>min/+</sup> mice to generate *Srebf2* Tg, *Apc*<sup>min/+</sup> mice. Strikingly, *Srebf2* Tg, *Apc*<sup>min/+</sup> mice developed more tumors than *Apc*<sup>min/+</sup> control mice at 12-week of age (Figure 7A and 7B) and had reduced hematocrits consistent with their elevated tumor burden (Figure S7E). Finally, we asked if blocking endogenous cholesterol biosynthesis would reduce tumor growth in *Lpcat3*<sup>F/F</sup>, *Cre*<sup>ERT2</sup>, *Apc*<sup>min/+</sup> mice. As shown in Figure 7C and 7D, Ro 48-8071 treatment decreased tumor numbers compared to vehicle treatment, implicating enhanced cholesterol synthesis as a major contributor to tumorigenesis in Lpcat3-deficient mice.

## Discussion

The fatty acyl chain composition of phospholipids determines membrane biophysical properties and influences various cellular processes. Previous studies have identified Lpcat3, a phospholipid-remodeling enzyme, as a critical determinant of polyunsaturated phospholipid abundance and membrane fluidity (Rong et al., 2013; Rong et al., 2015; Wang et al., 2016). Here we have shown that Lpcat3 also unexpectedly impacts ISC proliferation through control of cholesterol biosynthesis. We showed that increasing cellular cholesterol content is sufficient to drive ISC proliferation both *ex vivo* and *in vivo*, suggesting that cholesterol acts as a mitogen for ISCs. Finally we showed that Lpcat3 activity is important for suppressing *Apc*<sup>min</sup>-induced tumor formation. These findings outline a previously unrecognized link between phospholipid remodeling and cholesterol biosynthesis that regulate ISC homeostasis and tumorigenesis.

Lands' cycle, in which Lpcat3 participates, involves the hydrolysis of *sn*-2 fatty acids by phospholipase A2 (PLA2) and their re-acylation by lysophospholipid acyltransferases. A recent study has shown that overexpression of secreted phospholipase A2 (sPLA2, encoded by *Pla2g2a*) inhibits ISC function by suppressing Wnt signaling (Schewe et al., 2016). sPLA2 is highly expressed in Paneth cells and appears to act as a stem cell niche factor that indirectly affects ISC proliferation. However, whether the enzymatic activity of sPLA2 and its role in phospholipid remodeling is relevant for ISC function remains unknown. In the future it would be of interest to determine if the composition of membrane phospholipids—the

substrates of Pla2g2a—is altered in the intestines of mice deficient in this enzyme. We have shown that changes in phospholipid composition *per se* modulate ISC function. Individual phospholipid species differentially affect crypt organoid growth in culture, confirming that crypt hyperproliferation in the absence of Lpcat3 is a consequence of altered membrane composition. The fact that loss of Lpcat3 did not alter Wnt signaling nor increase the frequency of Paneth cells suggests that alterations in the stem cell niche may not contribute to increased proliferation in Lpcat3-deficient intestines. Rather, our data support a cell-autonomous effect due to altered phospholipid remodeling and increased cholesterol biosynthesis in ISCs and progenitor cells.

The mechanisms that link Lpcat3-dependent phospholipid remodeling to cholesterol biosynthesis in the intestine remain to be elucidated. Our data suggest that loss of Lpcat3 leads to changes in phospholipid composition that affect the activation of nuclear SREBP-2, perhaps by promoting processing. Recent studies have shown that ER phospholipid composition in liver is a determinant of SREBP-1 processing (Rong et al., 2017). In contrast these observations in liver, we observe a selective effect on SREBP-2 pathway activity in the intestine. Thus, the effects of phospholipid metabolism on SREBP-1 and SREBP-2 are likely to be complex and cell-type specific. Several signaling pathways have been shown to regulate SREBP activity in cancer cells, thereby linking cell proliferation with lipid biosynthesis, including the PI3K/AKT/mTOR and p53 pathways (Du et al., 2006; Freed-Pastor et al., 2012; Porstmann et al., 2008). Interestingly, prior studies have suggested that membrane phospholipid composition can modulate the activity of cellular signaling pathways, including the AKT pathway (Koeberle et al., 2013). It will be interesting to investigate if any of these signaling pathways may be involved in the effects of Lpcat3 on cholesterol biosynthesis.

The most surprising finding of this study was the mitogenic effect of cholesterol itself on ISC proliferation. Recent studies have suggested that ISC self-renewal may be linked to the availability of dietary nutrients. For example, a triglyceride-rich diet has been shown to activate the PPAR $\delta$  signaling pathway to enhance ISC and progenitor cell stemness and tumorigenesis (Beyaz et al., 2016), and calorie restriction facilitates ISC proliferation through mTORC1 and Sirt1 in Paneth cells and ISCs (Igarashi and Guarente, 2016; Yilmaz et al., 2012). Such studies suggest that organismal nutritional status and metabolism are coupled with ISC function. Our study substantiated this concept by showing that cholesterol availability modulates ISC proliferation. We showed that pharmacological inhibition of cholesterol biosynthesis dramatically suppressed crypt growth *in vivo* and *ex vivo*. On the other hand, increasing cholesterol content via dietary feeding or genetic activation of cholesterol biosynthesis enhanced ISC self-renewal.

It is to be expected that reducing the availability of cholesterol, an essential component of cell membranes, would impede crypt growth. On the contrary, the observation that simply providing more cholesterol to the cell drives proliferation is unexpected. Our data suggesting that the rate of endogenous cholesterol synthesis in ISCs is a limiting factor for proliferation under physiological conditions. At the same time, inhibition of cholesterol synthesis did not impair normal crypt proliferation in control mice, likely due to the availability of sufficient exogenous cholesterol to support the normal rate of proliferation. The details of how excess

cholesterol stimulates ISC proliferation remain to be determined. In a previous study, Hartman et al. demonstrated that dietary cholesterol regulates follicle stem cells proliferation in *Drosophila* by modulating the release of Hedgehog (Hh) protein (Hartman et al., 2013). Cholesterol homeostasis has also been linked to hematopoietic stem cell proliferation through regulating IL-23/G-CSF production (Westerterp et al., 2012; Yvan-Charvet et al., 2010). Interestingly, the Hedgehog pathway has been implicated in regulating ISC proliferation (Crosnier et al., 2006). Therefore, it will be interesting to investigate if excess cholesterol modulates the Hedgehog pathway or other signal transduction pathways in intestine. Another possibility is that cholesterol may regulate ISC function through conversion to a metabolite, such as 27-hydroxycholesterol, which has been shown to influence proliferation in cancer cells (Nelson et al., 2013). Further investigation will be needed to discriminate between these and alternative mechanisms.

ISCs have been demonstrated to be cells of origin for intestinal tumors. Our observations that *Lpcat3* deficiency and increased cholesterol biosynthesis dramatically enhance both ISC proliferation and *Apc<sup>min</sup>*-induced tumor formation are consistent with this notion. Cholesterol metabolism has long been linked with the risk of gastrointestinal cancer (Broitman, 1986; Jacobs et al., 2012; Mamtani et al., 2016). Although it is still under debate whether the use of statins reduces the risk of intestinal cancer, it is widely accepted that dietary cholesterol increases the risk. However, the underlying mechanisms are still not clear. We showed here that high cholesterol diet feeding increased cellular cholesterol levels in crypts and that cellular cholesterol content regulates the proliferation of ISCs. Thus, it is logical to hypothesize that dietary cholesterol presumably may promote tumorigenesis by modulating ISC homeostasis.

In conclusion, our findings highlight a link between phospholipid remodeling and cholesterol biosynthesis that regulates ISC function and tumorigenesis. Future studies will explore whether manipulating these metabolic axes could be used as a strategy for therapeutic intervention in gastrointestinal diseases.

## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Rabbit monoclonal anti-Olfm4	Cell Signaling	Cat# 39141S; RRID: AB_2650511
Rabbit polyclonal anti-Lysozyme	Dako	Cat# A0099; RRID: AB_2341231
Rabbit polyclonal anti-Chromogranin A	ImmunoStar	Cat# 20086; RRID: AB_572226
Rabbit polyclonal anti-cleaved caspase 3	Cell Signaling	Cat# 9661; RRID: AB_2341188
Rabbit monoclonal anti-Id1	BioCheck	Cat# BCH-1/37-2; RRID:AB_2713996
Rat monoclonal anti-Ly-6G	BioLegend	Cat# 127601; RRID:AB_1089179
Rat monoclonal anti-F4/80	BioLegend	Cat# 123101; RRID:AB_893504
Rabbit monoclonal anti-SREBP2	EMD Millipore	Cat#: MABS1988
F(ab)2-Goat anti-Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 555	Thermo Fisher Scientific	Cat# A-21430 RRID:AB_2535851

REAGENT or RESOURCE	SOURCE	IDENTIFIER
R.T.U. Biotinylated Goat Anti-Rat IgG Antibody	Vector laboratories	BP-9400
DAKO EnVision+ Single Reagents (HRP. Rabbit)	Agilent	K400311-2
Chemicals, Peptides, and Recombinant Proteins		
Tamoxifen	Sigma-Aldrich	T5648
Matrigel	Fisher	CB-40230C
JAG-1	Anaspec.	AS-61298
EGF Recombinant Mouse Protein	ThermoFisher	PMG8041
GlutaMAX™ Supplement	ThermoFisher	35050-061
Noggin	Peprotech	250-38
R-spondin	Thermo Fisher Scientific	4645-RS-025
Y-27632	Sigma-Aldrich	Y0503-1MG
N-Acetyl-L cysteine	Sigma-Aldrich	A7250-5g
B27	Thermo Fisher Scientific	12587-010
N2	Thermo Fisher Scientific	17502-048
4-hydroxytamoxifen	Sigma	H7904
Simvastatin	EMD Biosciences	567021-5MG
Ro 48-8071	Cayman Chemical	10006415
Methyl- $\beta$ -cyclodextrin	Cyclodextrin Technologies Inc	TRMB-P
Cholesterol	Sigma	C8667-1G
Mevalonolactone	Sigma	M4667-1G
IntestiCult™ Organoid Growth Medium (Mouse)	Stemcell technologies	6005
Critical Commercial Assays		
Prostaglandin E2 Parameter Assay Kit	Fisher	KGE004B
Amplex® Red Cholesterol Assay Kit	Life Technologies	A12216
Deposited Data		
Microarray data	This paper	GSE98516
Experimental Models: Organisms/Strains		
Mouse: Lpcat3 Floxed mice	Rong et al., 2015	N/A
Mouse: VillinCre-ERT2: Tg(Vil-cre/ERT2)23Syr	Generated by Sylvie Robine (Institut Curie) and provided by Nicholas Davidson (Washington University)	N/A
Mouse: C57BL/6J-ApcMin/J	The Jackson Laboratory	Stock No: 002020
Mouse: Srebf2 intestinal transgenic mice	Ma et al., 2014	N/A
Oligonucleotides		
See table S1		
Software and Algorithms		
GraphPad Prism	GraphPad Software	<a href="https://www.graphpad.com/scientificsoftware/prism/">https://www.graphpad.com/scientificsoftware/prism/</a>
ImageJ	NIH	<a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a>
Other		

REAGENT or RESOURCE	SOURCE	IDENTIFIER
ProLong® Diamond Antifade Mountant with DAPI	Thermo Fisher	P36966

## CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Peter Tontonoz (ptontonoz@mednet.ucla.edu).

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

### Mice

*Lpcat3<sup>fl/fl</sup>* mice were generated as described (Rong et al., 2015; Wang et al., 2016). *Lpcat3<sup>fl/fl</sup>* mice were crossed with Villin-*CreERT2* mice to generate *Lpcat3* tamoxifen inducible intestine-specific knockout (*Lpcat3<sup>fl/fl</sup>,CreERT2* or *CreERT2*) mice. *Lpcat3<sup>fl/fl</sup>,CreERT2* mice were crossed with *Apc<sup>min</sup>* mice to generate *Lpcat3<sup>fl/fl</sup>, Cre<sup>ERT2</sup>*, *Apc<sup>min</sup>* and *Lpcat3<sup>fl/fl</sup>, Apc<sup>min</sup>* control mice. Cre activity was induced by intraperitoneal injection with tamoxifen suspended in corn oil (1 mg/day for 5 days). *Srebf2* intestinal transgenic (*Srebf2*Tg) mice were described before (Ma et al., 2014). *Srebf2*Tg mice were crossed with *Apc<sup>min/+</sup>* mice to generate *Srebf2*Tg, *Apc<sup>min/+</sup>* mice. C57BL/6 wild-type were obtained from The Jackson Laboratory. All mice were housed under pathogen-free conditions in a temperature controlled room with a 12-hr light/dark cycle. All experiments were performed with male mice unless otherwise stated. Mice were fed a chow diet or a 1.25% cholesterol diet (Research Diets #C12826). Small intestines were excised and cut into three segments with length ratios of 1:3:2 (corresponding to duodenum, jejunum and ileum). Intestine tissues were frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$ , or fixed in 10% formalin, or frozen in OCT for cryosectioning. Tissue histology was performed in the UCLA Translational Pathology Core Laboratory. Animal experiments were conducted in accordance with the UCLA Animal Research Committee.

## METHOD DETAILS

### Crypt isolation and organoid culture

Crypts were isolated as described previously (Jabaji et al., 2013; Sato et al., 2009). Briefly, the proximal  $\sim 2/3$  of small intestine was harvested and flushed with ice-cold phosphate buffered saline (PBS). The intestine was cut into  $\sim 5$  cm fragments and washed with ice-cold PBS. The fragments were then incubated in 2.5 mM EDTA with gentle shaking at  $4^{\circ}\text{C}$  for 30 min.

The supernatant was removed, fragments were washed with 10 mL of cold PBS, and the sample was vortexed for 30 s with 3 s pulses. The fragments were allowed to settle, and the supernatant was set aside on ice as fraction 1. This process was repeated twice. The fractions were settled down on ice for  $\sim 10$  min and supernatant was filtered through  $70\ \mu\text{m}$  pore cell strainers (BD Biosciences, Bedford, MA). The filtrate was centrifuged at  $100\ g$  for 5 min, and the pellet was resuspended in 1 mL of basic medium, consisting of advanced Dulbecco's

modified Eagle medium (DMEM)/Ham's F12 (Thermo Fisher Scientific, #12634-010) with 2 mM GlutaMAX (Thermo Fisher Scientific, #35050-061), 10 mM HEPES (Thermo Fisher Scientific, #15630080).

Isolated crypts were counted and embedded in Matrigel (Thermo Fisher Scientific, #CB-40230C) at 10 crypts/ $\mu$ l. 150~200 crypts were plated per well of a 48-well plate and cultured in a crypt culture medium, DMEM/F12 (Thermo Fisher Scientific, #12634-010) supplemented with 2 mM GlutaMAX (Thermo Fisher Scientific, #35050-061), 10 mM HEPES (Thermo Fisher Scientific, #15630080), 1 $\times$  N2 (Thermo Fisher Scientific, #17502-048), 1 $\times$  B27 (Thermo Fisher Scientific, #12587-010), 1 mM N-Acetyl-L cysteine (Sigma-Aldrich, #A7250-5g), 50 ng/ml EGF (Thermo Fisher Scientific, #PMG8041), 100 ng/ml Noggin (Peprotech, #250-38), 500 ng/ml R-spondin (Thermo Fisher Scientific, #4645-RS-025), 1  $\mu$ M Jagged-1 (Anaspec, #61298), and 20 ng/ml Y-27632 (Sigma-Aldrich; #Y0503-1MG) (Figure 2 and 4) or IntestiCult™ Organoid Growth Medium (Mouse) (StemCell Technology, #06005) (Figure 5 and S5A). The medium was changed every other day. The results in Figure 2 and 5 are not directly comparable due to the fact that growth media from different commercial sources was used in the two experiments.

### Secondary organoid assay

The primary organoids were mechanically disassociated using a p200 pipette and pipetting 50–100 times. The cells were centrifuged, resuspended in Matrigel and replated as described above. Secondary organoids were quantified at day 4.

### Organoid measurement

The growth of organoids was evaluated as described with modifications (Lindemans et al., 2015). For organoid size evaluation, the surface area of organoid horizontal cross sections was measured. Organoid perimeters for area measurements were defined manually using ImageJ software. Four to five (2.5 $\times$ ) or ~8–10 (5 $\times$ ) non-overlapping images of all organoids in each well were acquired using a Zeiss Axio Observer Z1 inverted microscope. After 4–5 days in culture, total organoid numbers per well were counted under light microscopy to evaluate colony formation efficiency. The organoid structure was scored based on the number of buds under light microscopy: sphere (no budding), organoid 1 (one bud), organoid 2 (two buds) and organoid 3+ (three or more buds).

### Organoid treatment

Organoids were treated as described in the figure legends at the following concentrations: 100 nM 4-hydroxytamoxifen (4-OHT) (Sigma-Aldrich; #H7904), 50  $\mu$ M 16:0/18:0 (Avanti Polar Lipids, #850456) or 16:0/20:4 PC (Avanti Polar Lipids, #850459) liposome, 1  $\mu$ M Simvastatin (EMD Biosciences, #567021-5MG), 1  $\mu$ M Ro 48-8071 (Cayman Chemical, #10006415), 200  $\mu$ M mevalonic acid, 50  $\mu$ M cholesterol (Sigma-Aldrich, #C8667) solubilized in methyl- $\beta$ -cyclodextrin (M $\beta$ CD) (Cyclodextrin Technologies Inc., #TRMB-P). M $\beta$ CD-cholesterol complexes were prepared as described (Brown et al., 2002; Ito et al., 2015).

### EdU labeling and staining

Mice were i.p. injected with EdU (10 mg/kg) and sacrificed at 2 h, 24 h and 48 h post injection. Intestine tissues were frozen in OCT and cryosectioned (10  $\mu$ m). EdU staining was conducted using Click-iT™ EdU imaging kit (ThermoFisher cat# C10337) according to the manufacturer's protocol. Briefly, slides containing mounted frozen sections were allowed to thaw to room temperature, and then fixed with 4% paraformaldehyde in phosphate buffer saline (PBS) for 15 min. After washing twice with 3% bovine serum albumin (BSA) in PBS, the sections were permeabilized with 0.5% Triton X-100 in PBS for 20 min. The sections were again washed twice with 3% BSA in PBS and then incubated with a Click-iT™ reaction cocktail (Thermo Fisher Scientific, #C10337) containing Click-iT™ reaction buffer, CuSO<sub>4</sub>, Alexa Fluor® 488 Azide, and reaction buffer additive for 30 min while protected from light. The sections were washed once more with 3% BSA in PBS. For subsequent DNA staining, sections were washed once with PBS and then incubated with 5 $\mu$ g/mL Hoechst 33342 for 30 min. The slides were then washed twice with PBS and mounted with Vectashield (Vector Laboratories Inc).

### Immunohistochemistry and immunofluorescence

Fragments of jejunum were fixed overnight in 10% neutral-buffered formalin at room temperature, embedded in paraffin and sectioned. Sections were deparaffinized and subjected to antigen retrieval with 10 mM sodium citrate (pH 6.0) in a sub-boiling water bath for 20 minutes. Slides were then incubated with the primary antibodies overnight at 4°C unless stated otherwise. The primary antibodies used were rabbit anti-Olfm4 (1:500; Cell Signaling, #39141), rabbit anti-Lysozyme (1:400; Dako, #A0099), rabbit anti-Id1 (1:400; BioCheck, # BCH-1/37-2), rabbit anti-chromogranin A (1:500; Immunostar, #20086, incubated at room temperature for 45 min), rat anti-Ly6G (1:100; BioLegend, #127601), rat anti-F4/80 (1:100; BioLegend, #123101), and rabbit anti-cleaved caspase 3 (1:400; Cell Signaling #9661). For IHC staining, slides were further incubated with Envision+ System-HRP Labelled Polymer Anti-Rabbit (Agilent, # K400311-2) or R.T.U. Biotinylated Goat Anti-Rat IgG Antibody (Vector laboratories, # BP-9400) at room temperature for 1 h and developed with ImmPACT DAB Peroxidase (HRP) Substrate (Vector, #SK4105). For immunofluorescence staining, slides were further incubated with Alexa-555 conjugated F(ab')<sub>2</sub>-goat anti-rabbit IgG (H+L) cross-adsorbed secondary antibody (Thermo Fisher Scientific, #A21430). Microscopic images were obtained by a Zeiss Axioskop 2 plus fluorescent microscope, and positive cells were quantified by ImageJ software.

### Phosphatidylcholine liposome preparation

16:0; 18:0 PC and 16:0; 20:4 PC dissolved in chloroform were evaporated under argon stream to form a thin lipid film. Residual chloroform was thoroughly removed on a vacuum pump. The lipid film was resuspended in saline to 0.5 mM and incubated in 55 °C water bath with occasional vortex. Small unilamellar vesicles (SUV) were obtained with exclusion methods by passing PC suspension through a polycarbonate filter with 30 nm pore size for 10 times.

## Gene expression

Total RNA was isolated from tissues or organoids with Trizol (Invitrogen). cDNA was synthesized, and gene expression was quantified by real-time PCR with SYBR Green (Diagenode) and an ABI 7900. Gene expression levels were normalized to 36B4 or Actin. For microarray analysis, RNA from isolated crypts was pooled from  $n = 5$  biological replicates and processed in the UCLA Microarray Core Facility with Gene-Chip Mouse Gene 430.2 Arrays (Affymetrix). Data analysis was performed with GenespringGX (Agilent).

## Cell fractionation and western blot analysis

Cell fractionation of isolated crypts was performed following previous publication (Wang et al., 1994). Briefly, crypts were suspended in 0.5 ml buffer C (10 mM HEPES-KOH, pH 7.6, 1.5 mM MgCl<sub>2</sub>, 10 mM KCl, 0.5 mM dithiothreitol, 1 mM EDTA, 1 mM EGTA) supplemented with protease inhibitors, and disrupted by passage ten times through a 22-gauge needle, and centrifuged at 1000 g for 10 min. The crude nuclear pellet was extracted with 100  $\mu$ l buffer D (20 mM HEPES-KOH, pH 7.6, 25% glycerol, 0.5 M NaCl, 1.5 mM MgCl<sub>2</sub>, 1 mM EDTA, 1 mM EGTA) supplemented with protease inhibitors and centrifuged at 12,000 rpm for 30 min. The supernatant was nuclear extract. Twenty micrograms of total nuclear proteins were loaded on 4–12% gel and blotted with SREBP-2 antibody (EMD Millipore, #MABS1988).

## Free cholesterol content measurement

Total lipids were extracted from crypts as described by Bligh and Dyer (Bligh and Dyer, 1959). The crypt suspension in PBS was extracted by the addition of 3.75 ml of chloroform/methanol (1:2, v/v) and vortexed for 2 min. Chloroform (1.25 ml) was added and the suspension vortexed for additional 30 s. Then, 1.25 ml of 1.5 M NaCl was added to the mixture and vortexed for another 30 s. The mixture was centrifuged (500 g, 10 min) to separate the organic from the aqueous phase. The chloroform (lower) layer was collected for analysis. Free cholesterol content was measured with Amplex® Red Cholesterol Assay kit (Thermo Fisher scientific, #A12216).

## Phospholipid analyses

Isolated crypts were snap frozen in liquid nitrogen. Crypts were homogenized on ice in phosphate buffered saline. Homogenates were subsequently subjected to a modified Bligh-Dyer lipid extraction (Bligh and Dyer, 1959) in the presence of lipid class internal standards including eicosanoic acid, 1-0-heptadecanoyl-sn-glycero-3-phosphocholine, 1,2-dieicosanoyl-sn-glycero-3-phosphocholine, cholesteryl heptadecanoate, and 1,2-ditetradecanoyl-sn-glycero-3-phosphoethanolamine (Demarco et al., 2013). Lipid extracts were diluted in methanol/chloroform (4/1, vol/vol) and molecular species were quantified using electrospray ionization mass spectrometry on a triple quadrupole instrument (Thermo Fisher Quantum Ultra) employing shotgun lipidomics methodologies (Han and Gross, 2005). LysoPC molecular species were quantified as sodiated adducts in the positive ion mode using neutral loss scanning for 59.1 amu (collision energy = -28 eV). PC molecular species were quantified as chlorinated adducts in the negative ion mode using neutral loss



scanning for 50 amu (collision energy = 24 eV). Individual molecular species were quantified by comparing the ion intensities of the individual molecular species to that of the lipid class internal standard with additional corrections for type I and type II <sup>13</sup>C isotope effects (Han and Gross, 2005). Each molecular species indicated in data tables was confirmed by concomitant analyses of samples using product ion scanning for individual fatty acid constituents, including palmitoleic, palmitate, linoleate, oleate, stearate, arachidonate and docosahexadecanoate (product ion scans in m/z of 253.2, 255.2, 279.3, 281.3, 283.3, 303.4 and 327.4, respectively, at a collision energy + 35 eV).

### Prostaglandin E2 (PGE2) measurement

Small intestines were harvested and snap frozen in liquid nitrogen. Frozen samples were homogenized in 500 µl of cold PBS containing indomethacin (10 µg/ml) using a tissue homogenizer. The suspension was sonicated in an ice water containing bath sonicator for 20 cycles of 20 seconds of sonication with 20 seconds of cooling, followed by centrifugation for 10 minutes at 12,000 rpm. PGE2 levels in the supernatant was measured using a PGE2 ELISA Kit (Thermo Fisher Scientific, #KGE004B).

### Statistical analysis

For all studies, results from quantitative experiments were expressed as means ± SEM and were analyzed using Prism (GraphPad) computer software. Where appropriate, significance was calculated by Student's t test, one- or two-way ANOVA with Tukey's or Sidak's multiple comparison test.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments

This work was supported by NIH grants HL030568 and DK063491.

### References

- Barker N. Adult intestinal stem cells: critical drivers of epithelial homeostasis and regeneration. *Nat Rev Mol Cell Biol.* 2014; 15:19–33. [PubMed: 24326621]
- Barker N, Ridgway RA, van Es JH, van de Wetering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. *Nature.* 2009; 457:608–611. [PubMed: 19092804]
- Beyaz S, Mana MD, Roper J, Kedrin D, Saadatpour A, Hong SJ, Bauer-Rowe KE, Xifaras ME, Akkad A, Arias E, et al. High-fat diet enhances stemness and tumorigenicity of intestinal progenitors. *Nature.* 2016; 531:53–58. [PubMed: 26935695]
- Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. *Can J Biochem Physiol.* 1959; 37:911–917. [PubMed: 13671378]
- Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. *Nat Cell Biol.* 2015; 17:351–359. [PubMed: 25774832]
- Broitman SA. Dietary cholesterol, serum cholesterol, and colon cancer: a review. *Adv Exp Med Biol.* 1986; 206:137–152. [PubMed: 3296679]


- Brown AJ, Sun L, Feramisco JD, Brown MS, Goldstein JL. Cholesterol addition to ER membranes alters conformation of SCAP, the SREBP escort protein that regulates cholesterol metabolism. *Mol Cell*. 2002; 10:237–245. [PubMed: 12191470]
- Christian AE, Haynes MP, Phillips MC, Rothblat GH. Use of cyclodextrins for manipulating cellular cholesterol content. *J Lipid Res*. 1997; 38:2264–2272. [PubMed: 9392424]
- Chuang JC, Valasek MA, Lopez AM, Posey KS, Repa JJ, Turley SD. Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse. *Biochem Pharmacol*. 2014; 88:351–363. [PubMed: 24486573]
- Cohn SM, Schloemann S, Tessner T, Seibert K, Stenson WF. Crypt stem cell survival in the mouse intestinal epithelium is regulated by prostaglandins synthesized through cyclooxygenase-1. *J Clin Invest*. 1997; 99:1367–1379. [PubMed: 9077547]
- Cormier RT, Hong KH, Halberg RB, Hawkins TL, Richardson P, Mulherkar R, Dove WF, Lander ES. Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis. *Nat Genet*. 1997; 17:88–91. [PubMed: 9288104]
- Crosnier C, Stamatakis D, Lewis J. Organizing cell renewal in the intestine: stem cells, signals and combinatorial control. *Nat Rev Genet*. 2006; 7:349–359. [PubMed: 16619050]
- Demarco VG, Ford DA, Henriksen EJ, Aroor AR, Johnson MS, Habibi J, Ma L, Yang M, Albert CJ, Lally JW, et al. Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. *Endocrinology*. 2013; 154:159–171. [PubMed: 23142808]
- Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, Luongo C, Borenstein N, Dove W. Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. *Cell*. 1993; 75:631–639. [PubMed: 8242739]
- Du X, Kristiana I, Wong J, Brown AJ. Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: a link between a key cell proliferative pathway and membrane synthesis. *Mol Biol Cell*. 2006; 17:2735–2745. [PubMed: 16571675]
- el Marjou F, Janssen KP, Chang BH, Li M, Hindie V, Chan L, Louvard D, Chambon P, Metzger D, Robine S. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. *Genesis*. 2004; 39:186–193. [PubMed: 15282745]
- Fevr T, Robine S, Louvard D, Huelsken J. Wnt/beta-catenin is essential for intestinal homeostasis and maintenance of intestinal stem cells. *Mol Cell Biol*. 2007; 27:7551–7559. [PubMed: 17785439]
- Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. *Cell*. 2012; 148:244–258. [PubMed: 22265415]
- Gregorieff A, Liu Y, Inanlou MR, Khomchuk Y, Wrana JL. Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer. *Nature*. 2015; 526:715–718. [PubMed: 26503053]
- Han X, Gross RW. Shotgun lipidomics: electrospray ionization mass spectrometric analysis and quantitation of cellular lipidomes directly from crude extracts of biological samples. *Mass Spectrom Rev*. 2005; 24:367–412. [PubMed: 15389848]
- Hartman TR, Strohlich TI, Ji Y, Zinshteyn D, O'Reilly AM. Diet controls *Drosophila* follicle stem cell proliferation via Hedgehog sequestration and release. *J Cell Biol*. 2013; 201:741–757. [PubMed: 23690177]
- Holzer RG, Park EJ, Li N, Tran H, Chen M, Choi C, Solinas G, Karin M. Saturated fatty acids induce c-Src clustering within membrane subdomains, leading to JNK activation. *Cell*. 2011; 147:173–184. [PubMed: 21962514]
- Hong KH, Bonventre JC, O'Leary E, Bonventre JV, Lander ES. Deletion of cytosolic phospholipase A(2) suppresses Apc(Min)-induced tumorigenesis. *Proc Natl Acad Sci U S A*. 2001; 98:3935–3939. [PubMed: 11274413]
- Houchen CW, Stenson WF, Cohn SM. Disruption of cyclooxygenase-1 gene results in an impaired response to radiation injury. *Am J Physiol Gastrointest Liver Physiol*. 2000; 279:G858–865. [PubMed: 11052981]

- Igarashi M, Guarente L. mTORC1 and SIRT1 Cooperate to Foster Expansion of Gut Adult Stem Cells during Calorie Restriction. *Cell*. 2016; 166:436–450. [PubMed: 27345368]
- Ito A, Hong C, Rong X, Zhu X, Tarling EJ, Hedde PN, Gratton E, Parks J, Tontonoz P. LXR<sub>s</sub> link metabolism to inflammation through Abca1-dependent regulation of membrane composition and TLR signaling. *Elife*. 2015; 4:e08009. [PubMed: 26173179]
- Ito K, Suda T. Metabolic requirements for the maintenance of self-renewing stem cells. *Nat Rev Mol Cell Biol*. 2014; 15:243–256. [PubMed: 24651542]
- Jabaji Z, Sears CM, Brinkley GJ, Lei NY, Joshi VS, Wang J, Lewis M, Stelzner M, Martin MG, Dunn JC. Use of collagen gel as an alternative extracellular matrix for the in vitro and in vivo growth of murine small intestinal epithelium. *Tissue Eng Part C Methods*. 2013; 19:961–969. [PubMed: 23566043]
- Jacobs RJ, Voorneveld PW, Kodach LL, Hardwick JC. Cholesterol metabolism and colorectal cancers. *Curr Opin Pharmacol*. 2012; 12:690–695. [PubMed: 22884562]
- Jarvinen R, Knekt P, Hakulinen T, Rissanen H, Heliövaara M. Dietary fat, cholesterol and colorectal cancer in a prospective study. *Br J Cancer*. 2001; 85:357–361. [PubMed: 11487265]
- Kennedy BP, Payette P, Mudgett J, Vadas P, Pruzanski W, Kwan M, Tang C, Rancourt DE, Cromlish WA. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. *J Biol Chem*. 1995; 270:22378–22385. [PubMed: 7673223]
- Klein U, Gimpl G, Fahrenholz F. Alteration of the myometrial plasma membrane cholesterol content with beta-cyclodextrin modulates the binding affinity of the oxytocin receptor. *Biochemistry*. 1995; 34:13784–13793. [PubMed: 7577971]
- Koeberle A, Shindou H, Koeberle SC, Laufer SA, Shimizu T, Werz O. Arachidonoylphosphatidylcholine oscillates during the cell cycle and counteracts proliferation by suppressing Akt membrane binding. *Proc Natl Acad Sci U S A*. 2013; 110:2546–2551. [PubMed: 23359699]
- Lindemans CA, Calafiore M, Mertelsmann AM, O'Connor MH, Dudakov JA, Jenq RR, Velardi E, Young LF, Smith OM, Lawrence G, et al. Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. *Nature*. 2015; 528:560–564. [PubMed: 26649819]
- Ma K, Malhotra P, Soni V, Hedroug O, Annaba F, Dudeja A, Shen L, Turner JR, Khramtsova EA, Saksena S, et al. Overactivation of intestinal SREBP2 in mice increases serum cholesterol. *PLoS One*. 2014; 9:e84221. [PubMed: 24465397]
- MacPhee M, Chepenik KP, Liddell RA, Nelson KK, Siracusa LD, Buchberg AM. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. *Cell*. 1995; 81:957–966. [PubMed: 7781071]
- Mamtani R, Lewis JD, Scott FI, Ahmad T, Goldberg DS, Datta J, Yang YX, Boursi B. Disentangling the Association between Statins, Cholesterol, and Colorectal Cancer: A Nested Case-Control Study. *PLoS Med*. 2016; 13:e1002007. [PubMed: 27116322]
- Miyoshi H, VanDussen KL, Malvin NP, Ryu SH, Wang Y, Sonnek NM, Lai CW, Stappenbeck TS. Prostaglandin E2 promotes intestinal repair through an adaptive cellular response of the epithelium. *EMBO J*. 2017; 36:5–24. [PubMed: 27797821]
- Nelson ER, Wardell SE, Jasper JS, Park S, Suchindran S, Howe MK, Carver NJ, Pillai RV, Sullivan PM, Sondhi V, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. *Science*. 2013; 342:1094–1098. [PubMed: 24288332]
- Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, Griffiths JR, Chung YL, Schulze A. SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth. *Cell Metab*. 2008; 8:224–236. [PubMed: 18762023]
- Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. *Annu Rev Cell Dev Biol*. 2000; 16:459–481. [PubMed: 11031244]
- Rong X, Albert CJ, Hong C, Duerr MA, Chamberlain BT, Tarling EJ, Ito A, Gao J, Wang B, Edwards PA, et al. LXR<sub>s</sub> regulate ER stress and inflammation through dynamic modulation of membrane phospholipid composition. *Cell Metab*. 2013; 18:685–697. [PubMed: 24206663]
- Rong X, Wang B, Dunham MM, Hedde PN, Wong JS, Gratton E, Young SG, Ford DA, Tontonoz P. Lpcat3-dependent production of arachidonoyl phospholipids is a key determinant of triglyceride secretion. *Elife*. 2015:4.


- Rong X, Wang B, Palladino EN, de Aguiar Vallim TQ, Ford DA, Tontonoz P. ER phospholipid composition modulates lipogenesis during feeding and in obesity. *J Clin Invest.* 2017; 127:3640–3651. [PubMed: 28846071]
- Rowell CA, Kowalczyk JJ, Lewis MD, Garcia AM. Direct demonstration of geranylgeranylation and farnesylation of Ki-Ras in vivo. *J Biol Chem.* 1997; 272:14093–14097. [PubMed: 9162034]
- Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, van Es JH, Abo A, Kujala P, Peters PJ, Clevers H. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. *Nature.* 2009; 459:262–265. [PubMed: 19329995]
- Schewe M, Franken PF, Sacchetti A, Schmitt M, Joosten R, Bottcher R, van Royen ME, Jemmet L, Payre C, Scott PM, et al. Secreted Phospholipases A2 Are Intestinal Stem Cell Niche Factors with Distinct Roles in Homeostasis, Inflammation, and Cancer. *Cell Stem Cell.* 2016; 19:38–51. [PubMed: 27292189]
- Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, Ziegler PK, Canli O, Heijmans J, Huels DJ, Moreaux G, et al. Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-cell-like properties. *Cell.* 2013; 152:25–38. [PubMed: 23273993]
- Simons BD, Clevers H. Strategies for homeostatic stem cell self-renewal in adult tissues. *Cell.* 2011; 145:851–862. [PubMed: 21663791]
- Simons K, Toomre D. Lipid rafts and signal transduction. *Nat Rev Mol Cell Biol.* 2000; 1:31–39. [PubMed: 11413487]
- Spector AA, Yorek MA. Membrane lipid composition and cellular function. *J Lipid Res.* 1985; 26:1015–1035. [PubMed: 3906008]
- van der Flier LG, Haegerbarth A, Stange DE, van de Wetering M, Clevers H. OLFM4 is a robust marker for stem cells in human intestine and marks a subset of colorectal cancer cells. *Gastroenterology.* 2009; 137:15–17. [PubMed: 19450592]
- VanDussen KL, Carulli AJ, Keeley TM, Patel SR, Puthoff BJ, Magness ST, Tran IT, Maillard I, Siebel C, Kolterud A, et al. Notch signaling modulates proliferation and differentiation of intestinal crypt base columnar stem cells. *Development.* 2012; 139:488–497. [PubMed: 22190634]
- Wang B, Rong X, Duerr MA, Hermanson DJ, Hedde PN, Wong JS, Vallim TQ, Cravatt BF, Gratton E, Ford DA, Tontonoz P. Intestinal Phospholipid Remodeling Is Required for Dietary-Lipid Uptake and Survival on a High-Fat Diet. *Cell Metab.* 2016; 23:492–504. [PubMed: 26833026]
- Wang X, Sato R, Brown MS, Hua X, Goldstein JL. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. *Cell.* 1994; 77:53–62. [PubMed: 8156598]
- Westerterp M, Gourion-Arsiquaud S, Murphy AJ, Shih A, Cremers S, Levine RL, Tall AR, Yvan-Charvet L. Regulation of hematopoietic stem and progenitor cell mobilization by cholesterol efflux pathways. *Cell Stem Cell.* 2012; 11:195–206. [PubMed: 22862945]
- Yilmaz OH, Katajisto P, Lamming DW, Gultekin Y, Bauer-Rowe KE, Sengupta S, Birsoy K, Dursun A, Yilmaz VO, Selig M, et al. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. *Nature.* 2012; 486:490–495. [PubMed: 22722868]
- Yvan-Charvet L, Pagler T, Gautier EL, Avagyan S, Siry RL, Han S, Welch CL, Wang N, Randolph GJ, Snoeck HW, Tall AR. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. *Science.* 2010; 328:1689–1693. [PubMed: 20488992]
- Zhang N, Yantiss RK, Nam HS, Chin Y, Zhou XK, Scherl EJ, Bosworth BP, Subbaramaiah K, Dannenberg AJ, Benezra R. ID1 is a functional marker for intestinal stem and progenitor cells required for normal response to injury. *Stem Cell Reports.* 2014; 3:716–724. [PubMed: 25418719]

**Highlights**

- Lpcat3 and phospholipid remodeling regulate intestinal stem cell proliferation.
- Loss of Lpcat3 enhances cholesterol biosynthesis.
- Excess cholesterol increases intestinal stem cell proliferation.
- Lpcat3 deficiency and increased cholesterol synthesis promote tumorigenesis.



**Figure 1. *Lpcat3* deficiency induces hyperproliferation of intestinal crypt and ISCs**  
**(A)** Representative histology of Duodenum and Jejunum from *Lpcat3*<sup>F/F</sup> (F/F) and *Lpcat3*<sup>F/F</sup>, *CreERT2*<sup>+</sup> (*CreERT2*) mice 3 weeks after tamoxifen injection.  
**(B)** Quantification of crypt height and villus length in **a** (~50 crypts and ~20 villi per mouse, 4 mice/group).  
**(C)** Representative images and quantification of EdU staining of proliferating cells in crypts (~30 crypts from 3 mice/group). Tamoxifen-injected mice were i.p. injected with EdU (10 mg/kg) 2 h, 24 h and 48 h before sacrificing.  
**(D–E)** Representative images of immunohistochemistry (IHC) staining and quantification of Olfm4-positive and Id1-positive ISCs and progenitor cells in Jejunum from F/F and *CreERT2* mice 3 weeks after tamoxifen injection (~100 crypts from 4 mice/group). Values are means ± SEM. Statistical analysis was performed with Student's t test. \*  $P < 0.05$ , \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ ; \*\*\*\*  $P < 0.0001$ . Scale bars: 20 μm (D, E), 100 μm (A, C).



**Figure 2. Lpcat3 deficiency and saturated phosphatidylcholine (PC) promote crypt organoid growth *ex vivo***

(A) Representative images of day-7 organoids derived from F/F and *CreERT2* crypts.

(B–D) Quantification of the size (B,  $n=7$  mice/group) and number (C,  $n=11$  mice/group) and structure (D,  $n=5$  mice/group) of organoids derived from F/F and *CreERT2* crypts. Each dot represents the mean of 3–4 wells from one mouse. The organoid structure was scored based on the number of buds: sphere (no bud), organoid 1 (one bud), organoid 2 (two buds) and organoid 3+ (three or more buds).


(E) Representative images of day-5 organoids treated with PBS (control), saturated (16:0/18:0) PC, and polyunsaturated (16:0/20:4) PC (50  $\mu\text{M}$ ).

(F–H) Quantification of the structure (F,  $n=3$  mice/group) and size (G,  $n=6$  mice/group) and number (H,  $n=6$  mice/group) of organoids treated with PBS and different PC species. Each dot represents the mean of 3–4 wells from one mouse.

(I) Number of secondary organoids per dissociated primary organoid treated with PBS and different PC species ( $n=5$ ).

Values are means  $\pm$  SEM. Statistical analysis was performed with Student's t test (B and C) and two-way ANOVA (G-I). \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , \*\*\*\*  $P < 0.0001$ . Scale bars: 200  $\mu\text{m}$ .






**Figure 3. Loss of *Lpcat3* induces cholesterol biosynthetic pathway and increases free cholesterol content in crypts**

(A) Gene ontology (GO) analysis of upregulated genes (  $\geq 2$  fold) in *Lpcat3* deficient crypts identified by gene expression analysis. RNAs from 5 mice/group were pooled and subjected to microarray analysis.

(B) Diagram showing the relative expression of genes involved in cholesterol biosynthesis from the microarray analysis in (A).

(C) Expression of selective genes in cholesterol biosynthetic pathway in F/F and *CreERT2* crypts analyzed by realtime PCR (n=11 F/F mice, and 9 *CreERT2* mice).

- (D) Western blot analysis of nuclear SREBP-2 protein in crypts isolated from F/F and *CreERT2* intestines (n=5 mice/group).
- (E) Free cholesterol content in crypts isolated from F/F and *CreERT2* intestines (n=5 mice/group).
- (F) Expression of cholesterol biosynthetic genes in F/F and *CreERT2* organoids treated with vehicle (DMSO) or 4-hydroxytamoxifen (4-OHT, 100 nM) (n=7~8).
- Values are means  $\pm$  SEM. Statistical analysis was performed with Student's t test. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ .




**Figure 4. Inhibition of cholesterol biosynthesis rescues hyperproliferation of *Lpcat3* deficient crypts *ex vivo* and *in vivo***

(A) Representative images of *Lpcat3* deficient organoids treated with vehicle (DMSO), Simvastatin (Simv, Hmger inhibitor, 1  $\mu\text{M}$ ), Ro 48-8071 (Ro48, *Lss* inhibitor, 1  $\mu\text{M}$ ), or inhibitors supplemented with mevalonate (Mev, 200  $\mu\text{M}$ ) or M $\beta$ CD-cholesterol (Chol, 50  $\mu\text{M}$ ) (n=4 mice/group).

(B) Representative histology and quantification of crypt height in Jejunum of Control and *Lpcat3* deficient mice treated with vehicle or Ro48 (~50–100 crypts per mouse, 3 *CreERT2* and 2 F/F mice/group). Tamoxifen injected F/F and *CreERT2* mice were gavaged with vehicle or Ro48 (15 mg/kg/day) for 8 days before sacrificing.

(C) Representative images and quantification of EdU positive proliferating cells in Jejunum crypts (~50 crypts per mouse, 3 *CreERT2* and 2 F/F mice/group). Vehicle or Ro48 treated mice were i.p. injected with EdU (10 mg/kg) 2 h before sacrificing.

**(D)** Representative images of IHC staining and quantification of Olfm4 positive ISCs in Jejunum of *CreERT2* mice treated with vehicle or Ro48 (~50 crypts per mouse, 3 *CreERT2* and 2 F/F mice/group). Values are means  $\pm$  SEM. Statistical analysis was performed with two-way ANOVA (B–D). \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*\*  $P < 0.0001$ , n.s. not significant. Scale bars: 20  $\mu\text{m}$  (D), 100  $\mu\text{m}$  (B and C), and 200  $\mu\text{m}$  (A).



**Figure 5. Excess cholesterol promotes crypt organoid growth *ex vivo* and ISC proliferation *in vivo***

(A) Representative images and quantification of organoid size derived from wild-type mice treated with vehicle control (Ctrl) or M $\beta$ CD-Cholesterol (50  $\mu$ M) (n=4 mice). The connected points represent data from organoids derived from the same individual mouse.

(B) Representative images and quantification of EdU positive proliferating cells in Jejunum of chow or high cholesterol diet fed mice. C57BL/6 mice were fed chow or 1.25% cholesterol diet for 2 weeks before sacrificing (n=5, 7 mice/group, ~50 crypts per mouse).

(C) Representative images of IHC staining and quantification of Olfm4-positive ISCs in Jejunum of mice as in B.

(D) Representative images and quantification of EdU-positive proliferating cells in Jejunum of 10 weeks old WT and *Srebf2* intestinal transgenic (*Srebf2* Tg) mice (~50 crypts per mouse, 5 mice/group).

(E) Representative images of IHC staining and quantification of Olfm4-positive ISCs in Jejunum of WT and *Srebf2* Tg mice.

(F) Secondary organoid per primary organoid for M $\beta$ CD, Chol, and *Srebf2* Tg groups.


(E) Representative images of IHC staining and quantification of Olfm4 positive ISCs in Jejunum of WT and *Srebf2* transgenic mice (~40 crypts per mouse, 4 mice/group).

(F) Number of secondary organoids per dissociated WT primary organoids treated with M $\beta$ CD or M $\beta$ CD-cholesterol and from *Srebf2* Tg mice ( $n=6$ ).

Values are means  $\pm$  SEM. Statistical analysis was performed with unpaired Student's t test

(C), paired Student's t test (A) and one-way ANOVA. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*\*

$P < 0.0001$ , n.s. not significant. Scale bars: 20  $\mu\text{m}$  (C, E), 100  $\mu\text{m}$  (B, D), and 200  $\mu\text{m}$  (A).




**Figure 6. *Lpcat3* deficiency dramatically enhances tumor formation in the intestine**  
**(A)** Body weight change in tamoxifen-injected *Lpcat3*<sup>F/F</sup>, *CreERT2*, *Apc*<sup>min/+</sup> and *Lpcat3*<sup>F/F</sup>, *Apc*<sup>min/+</sup> mice (n=8, 9 mice/group).  
**(B)** Survival curve of tamoxifen-injected *Lpcat3*<sup>F/F</sup>, *CreERT2*, *Apc*<sup>min/+</sup> and *Lpcat3*<sup>F/F</sup>, *Apc*<sup>min/+</sup> mice (n=9, 11 mice/group).  
**(C)** Representative pictures of centrifuged blood from *Lpcat3*<sup>F/F</sup>, *CreERT2*, *Apc*<sup>min/+</sup> and *Lpcat3*<sup>F/F</sup>, *Apc*<sup>min/+</sup> mice 5 weeks post tamoxifen injection.  
**(D)** Hematocrit analysis of tamoxifen-injected mice as in C (n=4, 5 mice/group).  
**(E)** Quantification of tumor numbers in tamoxifen-injected mice as in C.  
**(F)** Representative gross images of duodenum and jejunum from tamoxifen-injected mice as in C.

**(G)** Representative images of H&E-stained histological sections (“Swiss roll” preparation) of duodenum and jejunum from mice as in C.

**(H)** Expression of selective genes in cholesterol biosynthetic pathway in *Lpcat3<sup>F/F</sup>*, *CreERT2*, *Apc<sup>min/+</sup>* and *Lpcat3<sup>F/F</sup>*, *Apc<sup>min/+</sup>* intestines analyzed by realtime RT-PCR (n=6, 7 mice/group).

Values are means  $\pm$  SEM. Statistical analysis was performed with Student’s t test (A, C, E and H) and Log-rank (Mantel-Cox) test (B). \*  $P < 0.05$ , \*\*\*  $P < 0.001$ , \*\*\*\*  $P < 0.0001$ , n.s. not significant. Scale bars: 400  $\mu$ m (G).





**Figure 7. Cholesterol availability is a key determinant of tumor formation in *Apc<sup>min/+</sup>* mice**  
**(A)** Representative gross images of duodenum and jejunum from *Srebf2 Tg, Apc<sup>min/+</sup>* and *Apc<sup>min/+</sup>* mice.  
**(B)** Quantification of tumor numbers in mice as in A (n=6, 7 mice/group).  
**(C)** Representative gross images of duodenum and jejunum from vehicle and Ro48 treated *Lpcat3<sup>F/F</sup>, CreERT2, Apc<sup>min/+</sup>* mice.  
**(D)** Quantification of tumor numbers in mice as in C (n=6 mice/group).  
 Values are means  $\pm$  SEM. Statistical analysis was performed with Student's t test (B, D). \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , \*\*\*\*  $P < 0.0001$ , n.s. not significant.